AR and plasma cell myeloma: In prostate cancer thymoquinone targets via the down-regulation of the androgen receptor (AR) and the proliferation regulator E2F-1 [25]; the (STAT3) pathway in human multiple myeloma cells [26]; JAK2 and c-Src in gastric cancer cells [27]; Bax up-regulation, Bcl-2 inhibition and activation of caspases in colorectal cancer [28]; inhibiting p38 MAPK in oral cancer [29]; activating p73 and UHRF1-dependent mitochondrial and cell cycle checkpoints in acute lymphoblastic leukemia [30,31], and the inhibition of the Notch signaling pathway in hepatic carcinoma [32].